CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,818,525 | -51.8% | 32,624 | -91.8% | 1.30% | -63.6% |
| Q2 2023 | $22,456,000 | -10.9% | 400,000 | +77.6% | 3.58% | +101.5% |
| Q3 2021 | $25,215,000 | -51.3% | 225,268 | -29.5% | 1.78% | -57.6% |
| Q2 2021 | $51,759,000 | +645.5% | 319,711 | +461.1% | 4.18% | +1688.5% |
| Q1 2021 | $6,943,000 | -60.7% | 56,984 | -50.6% | 0.23% | -69.9% |
| Q4 2020 | $17,654,000 | +83.1% | 115,300 | 0.0% | 0.78% | +11.5% |
| Q3 2020 | $9,644,000 | -26.7% | 115,300 | -35.6% | 0.70% | -33.3% |
| Q2 2020 | $13,162,000 | +73.3% | 179,100 | 0.0% | 1.05% | +83.4% |
| Q1 2020 | $7,596,000 | +0.8% | 179,100 | +44.8% | 0.57% | -53.2% |
| Q4 2019 | $7,534,000 | – | 123,700 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |